---
title: "AtriCure releases transcript of Q2 2026 earnings call"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293774266.md"
description: "AtriCure reported Q2 2026 revenue of USD 153.6 million, up 12.8%, and raised its full-year outlook with projected revenue between USD 602-610 million. The company highlighted a 27% growth in pain management and progress on the BoxX-NoAF trial, which has enrolled 500 patients. Additionally, appendage management saw a 14% increase, while MIS ablation remained pressured by PFA competition."
datetime: "2026-07-24T15:13:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293774266.md)
  - [en](https://longbridge.com/en/news/293774266.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293774266.md)
---

# AtriCure releases transcript of Q2 2026 earnings call

-   AtriCure’s Q2 2026 earnings call drew CEO Michael Carrel, CFO Angela Wirick, IR adviser Marissa Bych, analysts from Piper Sandler, BTIG, Canaccord, JPMorgan, Needham, Citizens JMP, Freedom, Oppenheimer. \* Q2 revenue USD 153.6 million, up 12.8%; adjusted EBITDA USD 27.3 million; net income USD 9 million; gross margin 77.2%. \* Raised 2026 outlook: revenue USD 602 million-USD 610 million; adjusted EBITDA USD 85 million-USD 89 million; EPS USD 0.05-USD 0.13; adjusted EPS USD 0.24-USD 0.32. \* BoxX-NoAF trial passed 500 patients, targeting 960 by year-end; data readouts expected in H1 2027; PMA submission planned with about 1-year review. \* Pain management grew 27% worldwide; cryoSPHERE MAX about 75% of US pain revenue; appendage management up 14%; MIS ablation stayed pressured by PFA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ATRC.US](https://longbridge.com/en/quote/ATRC.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [FRHC.US](https://longbridge.com/en/quote/FRHC.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares](https://longbridge.com/en/news/294417197.md)
- [AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year](https://longbridge.com/en/news/293959967.md)
- [AtriCure to join Needham Virtual MedTech & Diagnostics investor conference](https://longbridge.com/en/news/293928171.md)
- [AtriCure Q2 revenue beats estimates](https://longbridge.com/en/news/293661206.md)
- [Atricure Still Faces Broad, Evolving Risks Despite No Material Changes in 2025 10-K Disclosures](https://longbridge.com/en/news/294017350.md)